Bolt Biotherapeutics
BOLT
Bolt Biotherapeutics (BOLT) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$4.46
- EPS estimate
- −$6.30
- EPS surprise
- +29.21%
- Revenue surprise
- +119.58%
- Revenue
- $1.8M
- Revenue estimate
- $819,750.00
- Reported
- Aug 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 14, 2025 | −$6.30 | −$4.46 | +29.21% | $1.8M | SEC |
| Q1 2025 | May 12, 2025 | −$7.10 | −$5.80 | +18.31% | $1.2M | SEC |
| Q4 2024 | Mar 24, 2025 | −$7.60 | −$8.40 | −10.53% | $10,000.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$6.80 | −$8.00 | −17.65% | $1.1M | SEC |
| Q2 2024 | Aug 13, 2024 | −$8.76 | −$11.20 | −27.85% | $1.3M | SEC |
| Q1 2024 | May 14, 2024 | −$10.20 | −$5.60 | +45.10% | $5.3M | SEC |
| Q4 2023 | Mar 21, 2024 | −$9.40 | −$9.40 | +0.00% | $2.1M | SEC |
| Q3 2023 | Nov 9, 2023 | −$10.00 | −$8.60 | +14.00% | $2.5M | SEC |
| Q2 2023 | Aug 7, 2023 | −$9.53 | −$9.60 | −0.70% | $1.4M | SEC |
| Q1 2023 | May 11, 2023 | −$10.00 | −$9.00 | +10.00% | $1.8M | SEC |
| Q4 2022 | Mar 29, 2023 | −$11.73 | −$10.60 | +9.66% | $1.4M | SEC |
| Q3 2022 | Nov 10, 2022 | −$11.07 | −$11.60 | −4.82% | $2.1M | SEC |
| Q2 2022 | Aug 10, 2022 | −$13.15 | −$12.20 | +7.22% | $1.4M | SEC |
| Q1 2022 | May 12, 2022 | −$14.05 | −$12.80 | +8.90% | $813,000.00 | SEC |
| Q4 2021 | Mar 30, 2022 | −$16.16 | −$14.60 | +9.65% | $508,000.00 | SEC |
| Q3 2021 | Nov 9, 2021 | −$15.00 | −$12.60 | +16.00% | $752,000.00 | — |
| Q2 2021 | Aug 12, 2021 | −$11.70 | −$12.80 | −9.40% | $0.00 | — |
| Q1 2021 | May 13, 2021 | −$13.65 | −$21.80 | −59.71% | $0.00 | SEC |
| Q4 2020 | Mar 31, 2021 | −$12.87 | −$291.40 | −2164.76% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Bolt Biotherapeutics (BOLT) last report earnings?
Bolt Biotherapeutics last reported on Aug 14, 2025, covering fiscal Q2 2025.
Did BOLT beat earnings estimates?
Yes. Bolt Biotherapeutics reported EPS of −$4.46 for Q2 2025 against a −$6.30 estimate — a 29.21% beat.
How much revenue did BOLT report last quarter?
Bolt Biotherapeutics reported $1.8M in revenue for Q2 2025, against a consensus estimate of $819,750.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.